Published By
Created On
1 Aug 2023 20:23:03 UTC
Transaction ID
Cost
Safe for Work
Free
Yes
Dr. Subha Madhavan - VP & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics, Pfizer
Dr. Subha Madhavan, Ph.D. is Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data Management, at Pfizer ( https://www.pfizer.com/ ), where she works at the interface of science, technology, and business, helping to shape various aspects of their biopharma focus from small molecule design, to precision medicine, to global access in the future.
Dr. Madhavan’s responsibilities over her career have included initiating, designing, and executing several large national and international clinical research programs, including Cancer Moonshot, The Cancer Genome Atlas, Clinical Proteomic Tumor Analysis Consortium, and Human Cell Atlas, and she has put together an impressive portfolio of experience in oncology R&D, precision medicine, digital health, data science & analytics, bioinformatics, product development, clinical informatics, and health IT.
Before joining Pfizer, Dr. Madhavan was AstraZeneca's Head of Data Science, Oncology R&D where she led cross-functional teams in early oncology, clinical development, R&D strategy, precision medicine, and competitive intelligence in bringing life-changing therapies to patients.
Previously Dr. Madhavan was the Director of the Innovation Center for Biomedical Informatics (ICBI) at the Georgetown University Medical Center, Associate Professor in the Department of Oncology, and chief Data Scientist for the Georgetown University Medical Center with responsibility for all data-related research initiatives.
Dr. Madhavan has a Master’s degree in Computer Information Systems from University of Maryland and a Ph.D. in Molecular Biology and Biological Sciences from the Uniformed Services University for the Health Sciences through a highly ranked Indo-US Collaborative program. She received post-doctoral training in computational biology at Johns Hopkins University School of Medicine.
...
https://www.youtube.com/watch?v=yJpuoU-PwQk
Dr. Madhavan’s responsibilities over her career have included initiating, designing, and executing several large national and international clinical research programs, including Cancer Moonshot, The Cancer Genome Atlas, Clinical Proteomic Tumor Analysis Consortium, and Human Cell Atlas, and she has put together an impressive portfolio of experience in oncology R&D, precision medicine, digital health, data science & analytics, bioinformatics, product development, clinical informatics, and health IT.
Before joining Pfizer, Dr. Madhavan was AstraZeneca's Head of Data Science, Oncology R&D where she led cross-functional teams in early oncology, clinical development, R&D strategy, precision medicine, and competitive intelligence in bringing life-changing therapies to patients.
Previously Dr. Madhavan was the Director of the Innovation Center for Biomedical Informatics (ICBI) at the Georgetown University Medical Center, Associate Professor in the Department of Oncology, and chief Data Scientist for the Georgetown University Medical Center with responsibility for all data-related research initiatives.
Dr. Madhavan has a Master’s degree in Computer Information Systems from University of Maryland and a Ph.D. in Molecular Biology and Biological Sciences from the Uniformed Services University for the Health Sciences through a highly ranked Indo-US Collaborative program. She received post-doctoral training in computational biology at Johns Hopkins University School of Medicine.
...
https://www.youtube.com/watch?v=yJpuoU-PwQk
Author
Content Type
Unspecified
video/mp4
Language
English
More from the publisher
Controlling
VIDEO
DR NA
dr-najat-mokhtar-phd,-deputy-director
Dr. Najat Mokhtar Ph.D. is Deputy Director General, and Head of the Department of Nuclear Sciences and Applications, of the International Atomic Energy Agency (IAEA - https://www.iaea.org/), an international organization that seeks to promote the peaceful use of nuclear energy, and to inhibit its use for any military purpose, including nuclear weapons.
Prior to her appointment, Dr. Mokhtar was Director of the Division for Asia and the Pacific in the Department of Technical Cooperation of IAEA, and from 2012 to 2014, Dr. Mokhtar was the Section Head of Nutrition and Health related Environmental Studies, Human Health Division, at IAEA.
From 2010 to 2012, Dr. Mokhtar was the Director of Science and Technology at the Hassan II Academy of Science and Technology in Morocco, where she coordinated the national strategy on Education and Research. She worked as University Professor and Research Director at the University Ibn Tufail in Morocco for more than 20 years. Dr. Mokhtar was also a Technical Officer at the IAEA from 2001 to 2007.
Throughout her professional career, Dr. Mokhtar has contributed to the publication of several books (including the forward to the recent “Ionising Radiation and Mankind”), numerous peer reviewed publications, and she worked as a consultant for various organizations and national and international institutions (including Morocco's Ministry of Health and Ministry of Education, the World Food Program and Food and Agriculture Organization of the United Nations, USAID, WHO, and UNICEF). She was mandated by the Moroccan government as national coordinator to develop a "National Nutrition Strategy in Morocco 2011-2019", including training, education and research. In March 2011, she was elected President of the Moroccan Society of Nutrition.
Dr. Mokhtar holds a PhD in Nutrition and Endocrinology from Laval University in Canada and has a doctorate in food sciences from the University of Dijon in France. She has done her postdoctoral training as a Fulbright fellow at Johns Hopkins University in the United States of America.
...
https://www.youtube.com/watch?v=SSGiuAfkqVU
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR. D
dr.-douglas-willard-game-changing
Dr. Douglas E. Willard, PhD, (https://www.nasa.gov/directorates/spacetech/game_changing_development/about/program-leadership/doug-willard/) is Program Element Manager, Game Changing Development Program, Space Technology Mission Directorate, at the U.S. National Aeronautics and Space Administration (NASA).
The Game Changing Development (GCD) Program advances space technologies that may lead to entirely new approaches for the Agency’s future space missions and provide solutions to significant national needs. GCD collaborates with research and development teams to progress the most promising ideas through analytical modeling, ground-based testing and spaceflight demonstration of payloads and experiments and their efforts are focused on the mid Technology Readiness Level (TRL) range , generally taking technologies from initial lab concepts to a complete engineering development prototype. The Program employs a balanced approach of guided technology development efforts and competitively selected efforts from across academia, industry, NASA, and other government agencies.
GCD strives to develop the best ideas and capabilities irrespective of their source. The Program’s investment in innovative space technologies directly supports NASA’s mission to “Drive advances in science, technology, and exploration to enhance knowledge, education, innovation, economic vitality, and stewardship of Earth”. GCD’s focus on transformative space and science technologies will enable science missions and NASA’s Artemis Program. Additionally, GCD’s technology developments serve as a stimulus to the U.S. economy while providing inspiration and opportunity to our nation’s youth.
Previously, Dr. Willard was the Deputy Division Chief of the Laboratories, Development and Testing Division at the NASA’s Kennedy Space Center. He served in many leadership roles at Kennedy, including Chief Engineer for Research & Technology Development and Branch Chief of the Engineering Analysis Branch within the Engineering Directorate. He also served for many years as a research physicist in Kennedy’s Applied Physics Lab.
Dr. Willard received his doctorate in physics from the University of Central Florida.
...
https://www.youtube.com/watch?v=mrpc5fnBd_g
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR UW
dr-uwe-schoenbeck,-phd-cso-svp,-pfizer
Dr. Uwe Schoenbeck, Ph.D., (https://www.pfizer.com/research/science_and_technology/meet_our_scientists/uwe_schoenbeck) is Chief Scientific Officer, Emerging Science & Innovation (ES&I) and Senior Vice President, Worldwide Research and Development & Medical (WRDM) at Pfizer.
Part of Worldwide Research, Development & Medical, ES&I is charged with enhancing Pfizer’s pipeline through translation of external emerging science into breakthrough therapies for patients and through dedicated outreach to academia, consortia and biotech. Through its Emerging Science Liaisons located around the globe, they work across Pfizer’s Therapeutic Areas to harness external cutting edge pre-clinical assets and breakthrough technologies applying a broad range of partnering vehicles, including research collaborations, consortia, licensing, and acquisitions.
ES&I also engages in equity investments as well as seed investments and formation of new companies. It has a Target Sciences team which is focused on novel target and biology discovery research to introduce differentiated First-in-Class programs with enhanced confidence in rationale into the WRDM portfolio. And through its new Centers for Therapeutic Innovation (CTI - https://www.pfizercti.com/), ES&I prosecutes cutting edge science sourced from leading academic and medical centers globally, working in close partnership with external PIs and building an exciting pipeline across the range of Pfizer’s core areas.
Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team. Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women’s Hospital, Harvard Medical School. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles, book chapters and abstracts with particular contributions in molecular and cell biology, cardiovascular research, immunology and metabolism.
Dr. Schoenbeck earned his Ph.D. from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women’s Hospital, Harvard Medical School, before joining as a faculty member.
...
https://www.youtube.com/watch?v=IL3YS2tHwdo
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
ANGEL
angela-sheffield-ai-for-defense-nuclear
Angela Sheffield is a graduate student and Space Industry fellow at the National Defense University’s Eisenhower School. She is on detail from the National Nuclear Security Administration (NNSA), where she serves as the Senior Program Manager for AI for Defense Nuclear Nonproliferation Research and Development.
The National Nuclear Security Administration (https://www.energy.gov/nnsa/national-nuclear-security-administration), a United States federal agency, part of the U.S. Dept of Energy and it’s Office of Defense Nuclear Non-Proliferation, responsible for safeguarding national security through the military application of nuclear science.
NNSA maintains and enhances the safety, security, and effectiveness of the U.S. nuclear weapons stockpile; works to reduce the global danger from weapons of mass destruction; provides the United States Navy with safe and effective nuclear propulsion; and responds to nuclear and radiological emergencies in the United States and abroad.
In this position, Ms. Sheffield directs efforts leveraging artificial intelligence, advanced mathematics and statistics, and research computing technologies to develop capabilities to detect nuclear weapons development and characterize foreign nuclear programs around the world.
Before joining NNSA, Ms. Sheffield led project teams at DOE’s Pacific Northwest National Laboratory (PNNL) to develop modeling and simulation methodologies to model risk of WMD threats to inform national policy and decision making. Additionally, Ms. Sheffield led multidisciplinary efforts in the development of technical capabilities to detect the development of nuclear weapons with a special focus on AI and ML technologies.
Ms. Sheffield joined PNNL after a distinguished career as an operations research analyst in the U.S. Air Force, where she specialized in the research and development and technical intelligence of U.S. and adversary weapon systems.
Ms. Sheffield has a BS in Economics from the United States Air Force Academy and Duke University, an MS in Operations Research from Kansas State University, and will graduate from the Eisenhower School in June 2022 with an MS in National Security and Resource Strategy.
The views expressed here are those of the guest and do not reflect the position of the U.S. government, DOE, NNSA, or DoD.
...
https://www.youtube.com/watch?v=VeuQ3Z3uEhg
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR. #
dr.-madelynfernstrom-phd-nbc-news
Short from @Progress, Potential, and Possibilities - https://www.youtube.com/watch?v=_Tvz_l-kqf4&t=1s
...
https://www.youtube.com/watch?v=sx-f-eTd6i8
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR. M
dr.-moriba-jah,-ph.d.-space
Dr. Moriba Jah, Ph.D. (http://sites.utexas.edu/moriba/) is an Associate Professor of Aerospace Engineering and Engineering Mechanics at The University of Texas at Austin (https://www.ae.utexas.edu/people/faculty/faculty-directory/jah) where he is the holder of the Mrs. Pearlie Dashiell Henderson Centennial Fellowship in Engineering.
Dr. Jah also serves as Chief Scientific Advisor and Co-Founder (along with Apple co-founder Steve Wozniak) of Privateer (https://www.privateer.com/), a space-tech venture with a mission of driving space sustainability and creating solutions to make orbits around Earth safe and reliable.
With a Ph.D. from University of Colorado (Boulder) Dr. Jah is the director for Computational Astronautical Sciences and Technologies (CAST), a group within the Oden Institute for Computational Engineering and Sciences, where his team focuses on the broad themes of Orbital Mechanics, including Space object detection, tracking, identification, and characterization, as well as Spacecraft navigation. He is also the Lead for the Space Security and Safety Program at the Robert Strauss Center for International Security and Law.
Dr. Jah came to UT Austin by way of the Air Force Research Laboratory and NASA’s Jet Propulsion Laboratory prior to that, where he was a Spacecraft Navigator on a handful of Mars missions.
Dr. Jah is a Fellow of multiple organizations: TED, American Institute of Aeronautics and Astronautics (AIAA), American Astronautical Society (AAS), International Association for the Advancement of Space Safety (IAASS), Royal Astronomical Society (RAS), and the Air Force Research Laboratory (AFRL). He has served on the US delegation to the United Nations Committee On Peaceful Uses of Outer Space (UN-COPUOS), is an elected Academician of the International Academy of Astronautics (IAA), and has testified to congress on his work as related to Space Situational Awareness and Space Traffic Management.
Dr. Jah is a Co-Editor of the IAA and Elsevier Acta Astronautica journal, and serves on multiple committees: IAA Space Traffic Management, IAA Space Debris, AIAA Astrodynamics, IAF Astrodynamics, and IAF Space Security.
...
https://www.youtube.com/watch?v=shSeCu85v-4
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR VE
dr-veronica-rodriguez-bravo-phd-nuclear
Dr. Veronica Rodriguez-Bravo, PhD, is Assistant Professor, Department of Cancer Biology, at the Sidney Kimmel Cancer Center, Thomas Jefferson University, in Philadelphia, PA, USA. (https://sidneykimmelcancercenter.jeffersonhealth.org/)
Dr. Rodriguez-Bravo obtained her PhD in Pathology and Cell Biology (Summa Cum Laude) from the University of Barcelona in 2007, where she also received the Extraordinary Doctorate Award for her studies on the distinct DNA replication checkpoint mechanisms of tumor cells. During her postdoctoral training at the Experimental Oncology Department of the University Medical Center of Utrecht (UMC, The Netherlands) and at the Molecular and Cell Biology Programs of Memorial Sloan Kettering Cancer Center (MSKCC, New York), she specialized in the study of chromosome segregation during mitosis and the role of nuclear pores in genome integrity maintenance.
Dr. Rodriguez-Bravo's post-doctoral work allowed her to apply genome-editing techniques crucial to dissect the function of mitotic and nuclear pore proteins in chromosomal stability and resulted in the recognition with the Memorial Sloan Kettering Cancer Center Postdoctoral Research Award.
Dr. Rodriguez-Bravo’s research focuses on the study of genome integrity maintenance mechanisms and the relationship of defects in cell division to cancer pathogenesis with special emphasis in the pathways contributing to cancer cells’ more aggressive phenotypes.
...
https://www.youtube.com/watch?v=_vXeP_O4Zrc
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
SHANE
shane-bigelow-ceo,-vital-chain
Shane Bigelow is the CEO of Ownum (https://www.ownum.com/), a Cleveland-based company that helps government become more efficient by converting paper-based processes to digital formats using blockchain.
Prior to Ownum, Mr. Bigelow was a Senior Vice President and Managing Director at Bernstein, where he managed a part of that firm’s U.S. business and sat on the firm’s Responsible Investment Committee that focused on the United Nation’s Principles for Responsible Investment; Environmental, Social and Governance Issues (ESG); and Socially Responsible Investment matters. There, he developed a highly informed view of how blockchain technologies can help society through reducing the costs of government, which informs the business at Ownum today.
Under the Ownum umbrella, Mr. Bigelow is the CEO of a startup called Vital Chain (https://www.vitalchain.com/) which is focused on making medical record data more user-friendly by enabling fast, secure, and digitally verified paths to acquire and use it, enabling economic progress and expense savings for all members of the healthcare record ecosystem – patients, hospitals, and medical data users. Ultimately, they want to end the reliance on the legacy paper-based system to manage vital records, providing a digital record and validated proof of an individual's life and health status.
Prior to Bernstein, Mr. Bigelow was the global financial products manager for Cisco Systems Capital (a subsidiary of Cisco Systems, Inc.). He graduated cum laude with a finance degree and a concentration in international business from the University of Notre Dame and holds an MA in international political economy and development from Fordham University.
Mr. Bigelow is a member of the board for Bluecoats, The Northeast Ohio Foundation for Patriotism (NEOPAT), the Gesu School Endowment Fund, where he is President, and the Lincoln Hall Foundation, where he is chairman of the investment committee. He has additionally been involved with the United Way of Greater Cleveland as a member of their campaign committee, is an alumnus of Leadership Cleveland, is a member of the Greater Cleveland Partnership’s Commission on Economic Inclusion and is an alum of the FBI Citizen’s Academy.
...
https://www.youtube.com/watch?v=Vnzzd1rALM4
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English
Controlling
VIDEO
DR. R
dr.-roger-schechter,-md.-cmo,-exocel-bio
Dr. Roger Schechter, MD. is the Chief Medical Officer at Exocel Bio, a company that is merging knowledge emerging from the exciting space of exosomes and nanoparticle technology for therapeutic applications in cellular regeneration.
Dr. Schechter also serves as Medical Director for Wound Management at Palomar Health in San Diego, Chief Medical Officer at Synergy Wound Technology, and with his medical degree from University of California, San Diego and training in Emergency Medicine, he practices full time as a Wound Care and Hyperbaric Medicine Physician. He has been in active wound care practice and research for the past 19 years and practices across the continuum of wound management in outpatient, inpatient and long term care.
In addition to those roles, Dr. Schechter concurrently serves as a consultant to industry, helping to bridge the divides that separate the clinical, basic research, and business aspects of wound care for biotechnology companies and digital health application firms. In that capacity he is involved in protocol development, providing marketing insight, and assistance with strategic planning, and health economic outcomes research.
Dr. Schechter is a speaker on the national level regarding wound care, advanced wound care modalities, and non-invasive vascular testing, and has spoken internationally about clinical research. Dr. Schechter also provides science based educational programs on behalf of wound care product manufacturers.
Dr. Schechter also frequently serves as a medical legal expert regarding wound management. He has provided evaluation, advice to counsel, and testimony regarding the standard of care on over 80 cases involving allegations of medical malpractice and elder abuse in relation to development of chronic wounds and skin breakdown of all etiologies.
Based on his experience as a medico-legal expert, Dr. Schechter provides risk management consulting for Acute Care and Long Term Care. He also offers a lecture series dedicated to Wound and Skin Breakdown Risk Management for Post-Acute Care, a curriculum designed to convey unique strategies for avoiding and/or mitigating litigation, as well as regulatory sanction, and/or mitigating litigation, as well as regulatory sanction.
...
https://www.youtube.com/watch?v=aQW1D6q_F8A
Transaction
Created
2 weeks ago
Content Type
Language
video/mp4
English